Karyopharm Therapeutics | KPTI - مصروفات التشغيل





مصروفات التشغيل تغيير تاريخ
AbbVie USD 10.81B 13.45B 2025-12
Abbott USD 9.21B 17M 2025-12
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Incyte USD 1.12B 3.53B 2025-12
J&J USD 18.97B 2.38B 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 10.16B 558M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Novartis USD 9.8B 61M 2025-12
Novartis USD 9.8B 23M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Takeda JPY 1.02T 400.98B 2025-12
Tectonic Therapeutic USD 21.52M 374K 2025-12
TG Therapeutics USD 142.08M 9.74M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Xencor USD 81.86M 13.35M 2025-12